Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology

Chao, Ariana M.; Wadden, Thomas A.; Walsh, Olivia; Gruber, Kathryn; Alamuddin, Naji; Berkowitz, Robert I.; Tronieri, Jena Shaw

doi:10.1002/oby.22653

Cited by 32 publications

(29 citation statements)

References 28 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additional studies are needed to identify best responders for participants with two or more phenotypes or those with no phenotype, which may require a low-calorie diet challenge to trigger a metabolic adaptation or weight-loss-induced phenotype. Additional, further studies are needed to understand whether AOMs with multiple mechanisms of action may have a positive outcome in other phenotypes, for example, using bupropion-naltrexone sustained release to induce satiation (41) or liraglutide for food cravings (42). However, the benefits seen with a phenotype-guided approach over standard of care warrant the additional testing in the management of obesity.…”

Section: Discussionmentioning

confidence: 99%

Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic

Acosta

Camilleri

Dayyeh

et al. 2021

Obesity

View full text Add to dashboard Cite

Little is known about the predictors of response to obesity interventions. Methods: In 450 participants with obesity, body composition, resting energy expenditure, satiety, satiation, eating behavior, affect, and physical activity were measured by validated studies and questionnaires. These variables were used to classify obesity phenotypes. Subsequently, in a 12-month, pragmatic, real-world trial performed in a weight management center, 312 patients were randomly assigned to phenotype-guided treatment or non-phenotype-guided treatment with antiobesity medications: phentermine, phentermine/topiramate, bupropion/naltrexone, lorcaserin, and liraglutide. The primary outcome was weight loss at 12 months. Results: Four phenotypes of obesity were identified in 383 of 450 participants (85%): hungry brain (abnormal satiation), emotional hunger (hedonic eating), hungry gut (abnormal satiety), and slow burn (decreased metabolic rate). In 15% of participants, no phenotype was identified. Two or more phenotypes were identified in 27% of patients. In the pragmatic clinical trial, the phenotype-guided approach was associated with 1.75-fold greater weight loss after 12 months with mean weight loss of 15.9% compared with 9.0% in the non-phenotype-guided group (difference −6.9% [95% CI −9.4% to −4.5%], P < 0.001), and the proportion of patients who lost >10% at 12 months was 79% in the phenotype-guided group compared with 34% with non-phenotype-guided treatment group. Conclusions: Biological and behavioral phenotypes elucidate human obesity heterogeneity and can be targeted pharmacologically to enhance weight loss.

show abstract

Section: Discussionmentioning

confidence: 99%

Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic

Acosta

Camilleri

Dayyeh

et al. 2021

Obesity

View full text Add to dashboard Cite

show abstract

“…Since all these studies differed in methodology and participants had comorbidities, it is hard to comment on the efficacy of impulsivity-focused pharmacotherapy approaches. Findings of two studies comparing medication with psychotherapy [ 34 , 36 ] did not provide evidence for a superiority of impulsivity-focused medication, although the coupling with psychotherapy seems promising and effective.…”

Section: Resultsmentioning

confidence: 99%

“…The studies investigating the efficacy of pharmacotherapy to decrease binge eating episodes have different methodologies making it hard to draw a conclusion. Though Glucagon-like peptide-1 [ 34 , 35 ] and methylphenidate [ 36 ] seem helpful to reduce food cravings, administration of these medications appears not to result in a greater improvement when compared to psychotherapeutic approaches [ 34 , 36 ]. Moreover, review studies on pharmacological approaches for the treatment of binge eating suggest that topiramate as an antagonist of kainate/AMPA glutamate receptor is able to reduce binge eating frequency by suppressing appetite [ 46 , 47 ].…”

Section: Discussionmentioning

confidence: 99%

“…Trait impulsivity was not significantly reduced in any group. Pharmacotherapy approach Chao et al (2019) [ 34 ] N = 150 obese adults with binge eating IBT-alone vs. IBT-liraglutide vs. Multicomponent (IBT + liraglutide + portion-controlled diet) 21 sessions of IBT vs. 21 sessions of IBT + 3.0 mg/d as a once-daily vs. 21 sessions of IBT + 3.0 mg/d as a once-daily + 12-week, 1000- to 1200-kcal/d diet 1. EDEQ (binge eating episodes) 1.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Can we change binge eating behaviour by interventions addressing food-related impulsivity? A systematic review

İnce

Schlatter²,

Max

et al. 2021

J Eat Disord

View full text Add to dashboard Cite

Background An extensive amount of research has underlined the potential role of impulsivity in the development and maintenance of binge eating behaviour. Food-related impulsivity has particularly received attention given its close relationship with overeating and binge eating episodes. Besides the available evidence, our understanding regarding the effectiveness of treatment modalities for binge eating targeting impulsivity and related constructs (e.g., food craving, inhibitory control, and reward sensitivity) is limited. Thus, this systematic review aimed to investigate whether binge eating behaviour is changeable by interventions that are impulsivity-focused and food-related and whether one of these interventions is superior to the others. Method A search on PubMed and PsycINFO was performed for relevant articles published up to September 2020. Studies delivering food-related impulsivity treatment to individuals suffering from binge eating episodes and including a control condition without this treatment were investigated. Following the search, 15 studies meeting the eligibility criteria were analysed. Results Analyses revealed that available impulsivity-focused approaches can be categorised as psychotherapy, pharmacotherapy, computer-assisted cognitive training, and direct neuromodulation interventions. Regarding their effectiveness, it appeared that all of these approaches might be promising to change food-related impulsivity in individuals with binge eating episodes, particularly to decrease binge eating symptoms. However, a superior intervention approach in this early state of evidence could not be determined, although food-related cue exposure, transcranial direct current stimulation, and the combination of several interventions seem fruitful. Conclusion Efforts to treat binge eating behaviour with interventions focusing on food-related impulsivity appear to be promising, particularly concerning binge eating frequency, and also for food craving and inhibitory control. Given limited research and varying methods, it was not possible to conclude whether one impulsivity-focused intervention can be considered superior to others.

show abstract

“…Universidade do Sul de Santa Catarina (UNISUL), Tubarão -SC 5. Pontifícia Universidade Católica de Goiás (PUC-GO), Goiânia -GO 6. Faculdade de Ciências Médicas e da Saúde de Juiz de Fora (FCMS/JF), Juiz de Fora -MG 7.…”

unclassified

Obesidade: diagnóstico e tratamento farmacológico com Liraglutida, integrado a terapia comportamental e mudanças no estilo de vida

et al. 2021

View full text Add to dashboard Cite

Objetivo: Discorrer sobre a integração da Terapia Comportamental Intensiva para Obesidade (IBT) em conjunto com a farmacoterapia (Liraglutida) e mudanças no estilo de vida para o tratamento de pacientes obesos. Revisão bibliográfica: A obesidade é uma doença inflamatória crônica que teve um aumento significativo nos últimos anos e que representa um fator de risco aumentado para diabetes tipo 2, doenças cardiovasculares, câncer e apneia do sono. O tratamento da obesidade deve ser realizado de forma individual e multidisciplinar, integrando a IBT com a farmacoterapia, em casos de IMC>30 kg/m² ou com IMC>27kg/m² com comorbidade associada. Dentre os fármacos análogos ao GLP-1 existentes, a liraglutida é uma das substâncias mais conhecidas e amplamente difundidas em associação com a IBT, dobrando a média de perda de peso (11,5%) em pacientes obesos a curto prazo e, quando incluídas a readequação alimentar e exercícios físicos, foram observadas melhoras a longo prazo. Considerações finais: A Liraglutida é um importante medicamento para induzir e manter a perda de peso em pacientes obesos, contudo é um medicamento de aplicação subcutânea e de alto custo.

show abstract

Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology

Cited by 32 publications

References 28 publications

Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic

Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic

Can we change binge eating behaviour by interventions addressing food-related impulsivity? A systematic review

Obesidade: diagnóstico e tratamento farmacológico com Liraglutida, integrado a terapia comportamental e mudanças no estilo de vida

Contact Info

Product

Resources

About